377 related articles for article (PubMed ID: 18086120)
21. [Correlation of HBV DNA level and viral breakthrough during lamivudine therapy for chronic hepatitis B].
Park HS; Lee DH; Heo J; Kim GH; Kang DH; Song GA; Cho M
Korean J Hepatol; 2006 Jun; 12(2):173-83. PubMed ID: 16804342
[TBL] [Abstract][Full Text] [Related]
22. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea].
Jung S; Suh DJ; Park HJ; Park YH; Song HG; Lee HC; Chung YH; Lee YS
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):418-27. PubMed ID: 12506246
[TBL] [Abstract][Full Text] [Related]
24. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
Kilic ZM; Kuran S; Akdogan M; Cicek B; Oguz D; Odemis B; Sasmaz N
Adv Ther; 2008 Mar; 25(3):190-200. PubMed ID: 18385953
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
26. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
[TBL] [Abstract][Full Text] [Related]
27. Lamivudine for patients with chronic hepatitis B and advanced liver disease.
Liaw YF; Sung JJ; Chow WC; Farrell G; Lee CZ; Yuen H; Tanwandee T; Tao QM; Shue K; Keene ON; Dixon JS; Gray DF; Sabbat J;
N Engl J Med; 2004 Oct; 351(15):1521-31. PubMed ID: 15470215
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of long-term lamivudine therapy in the patients with decompensated liver cirrhosis secondary to hepatitis B].
Park TW; Park YM; Bae SH; Jang JW; Nam SW; Choi JY; Yoon SK; Cho SH; Yang JM; Han NI; Ahn BM; Lee YS; Lee CD; Park DH
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):428-35. PubMed ID: 12506247
[TBL] [Abstract][Full Text] [Related]
30. [One year and half treatment with lamivudine in active cirrhosis resulting from chronic hepatitis B].
Zeng WQ; Guo SH; Zhang DZ; Zhou Z; Ren H; Zhang QH; Wang ZY
Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):176-8. PubMed ID: 12681069
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
[TBL] [Abstract][Full Text] [Related]
32. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
Yao FY; Terrault NA; Freise C; Maslow L; Bass NM
Hepatology; 2001 Aug; 34(2):411-6. PubMed ID: 11481627
[TBL] [Abstract][Full Text] [Related]
33. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
[TBL] [Abstract][Full Text] [Related]
34. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
[TBL] [Abstract][Full Text] [Related]
35. [Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy].
Chen JL; Wang L; Yan J; Zhang L; Yu H; Fan XL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):273-5. PubMed ID: 17971944
[TBL] [Abstract][Full Text] [Related]
36. Danshao huaxian capsule in treatment of decompensated cirrhosis resulting from chronic hepatitis B.
Cheng ML; Lu T; Yao YM; Geng XX
Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):48-51. PubMed ID: 16481282
[TBL] [Abstract][Full Text] [Related]
37. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
Eun JR; Lee HJ; Kim TN; Lee KS
J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
[TBL] [Abstract][Full Text] [Related]
38. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
[TBL] [Abstract][Full Text] [Related]
39. Additional benefit of lamivudine treatment as a preventive therapy for hepatic encephalopathy in patients with decompensated liver cirrhosis associated with hepatitis B.
Hanada S; Kumashiro R; Kaji R; Harada M; Sata M
Int J Mol Med; 2002 Nov; 10(5):647-8. PubMed ID: 12373309
[TBL] [Abstract][Full Text] [Related]
40. [The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis].
Ma H; Guo F; Wei L; Sun Y; Wang H
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1832-5. PubMed ID: 17922993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
